TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of HIV-infected individuals demonstrating the booster effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of patients who decide to enroll in a clinical study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of study participants who remain in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perianesthesia Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quantity of anti-HLA-DR antibodies per cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MiRNA-124 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: let-7a level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal heat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression levels of LNK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein expression levels of LNK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator Clinical Grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in FACT/GOG-Neurotoxicity subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal morbidity related to placenta accreta spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients presenting weaning-induced pulmonary edema or weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean and standard deviation of T time between fluid depletion and consolidated weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of intrahepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes in hepatic steatosis composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first need for Rescue Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity assessed by the Physician Global Assessment (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients attaining the composite endpoint of lupus low disease activity (LLDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quick Dementia Rating System (QDRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Functional Activities Questionnaire (FAQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of intraoperative lung congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: msSBP lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified Rebound Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum vitamin D (25-hydroxy vitamin D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Iron (including Ferritin, Total Iron Binding Capacity (TIBC) and Transferrin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of normokalaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accumulated heart rate-based load measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Lu-PSMA-617
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Androgen deprivation therapy (ADT)-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Testosterone hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of participants requiring additional doses of randomized pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetics of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement per participant in the Facebook group
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Intervention Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of multiple doses of STK-001
Endpoint domain: Adverse events/effects
Primary endpoint: Drug-negative saliva tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in treatment expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in treatment credibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Selective Voluntary Motor Control of the Upper Extremities (SCUES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Fear of Falling Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in percent of the 95th percentile for BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of combined minutes per day of moderate and vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of saliva IgA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of serum functional neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of serum Anti-Spike IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of anti S-RBD IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of serum Anti-Nucleocapsid IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Baseline level of Anti-Ad5 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normal reference range for the 50g Sucrose Challenge Test (SCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal cutoff values for the 50g Sucrose Challenge Test (SCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal reference range for the 50g 13C-Sucrose Breath Test (CBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal cutoff values for the 50g 13C-Sucrose Breath Test (CBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Blood Hemoglobin (g/dl) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SARS-CoV-2 Novel coronavirus S protein antibody (IgG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Engagement and satisfaction with the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast cancer risk perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recurrent TIA or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Self-injurious thoughts and behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intervention score on the Maslach Burnout Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-intervention score on the Profile of Mood States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-intervention score on the Depression Anxiety Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Rate of Drug-Drug Interactions and Drug-Gene Interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of Diabetes on the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New or enlarging T2 hyperintense lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant Grade 3 or higher lab abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative Mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Fine motor praxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physicians' knowledge of antibiotic resistance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude and practice of physicians regarding antibiotic prescription
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of a dysbiosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Characterization of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive value of fragmented atrial potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic Function measured as Left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in vascular compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of interstitial lung disease
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal sleep-wake state scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: participant engagement in the peer recovery support program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: participant acceptability of the peer recovery support program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Certified Recovery Specialist fidelity to peer recovery support program components
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: aMMP-8 levels in mouth rinse samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic change of gut microbiome: a-diversity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic change of gut microbiome: b-diversity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune modulation in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune modulation in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive and Negative Syndrome Scale (PANSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR) Rate Post-ASCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IOWA Conners Rating Scale (Inattention/Overactivity subscale) rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of patient-ventilator asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neural PIT effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral full-lever specific and general PIT effect
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: social communication abilities (according to parents)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: social communication abilities (evaluated by clinician)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Covid-19 antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants preferring self-collection to provider collection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of Amyvid deposition in GBM tumor structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation of Amyvid deposition with components of high metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of Amyvid deposition with components of increased vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reversal of complete heart block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bilateral occurrence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Success of implanting a single chamber lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: optimal patch test concentration for allergic contact dermatitis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: threshold value for development of allergic contact dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Indexed left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting-state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of sensory-evoked hemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Alpha-diversity of Respiratory Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Change in Beta-diversity of Respiratory Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Change in Respiratory Bacterial Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Lower Extremity Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life of Individual
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: B-natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Consideration of Future Consequences Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Infants With Identified High-Risk Factors for Clostridium difficile Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of effective analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-STARTS composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from resting blood glucose to 48 hours after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from resting fat oxidation to 90 minutes after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from resting markers of glucose metabolism to 90 minutes after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and Severity of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Butyrate production measured by enzyme expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Butyrate production measured by short-chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increases in butyrate producers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Determine the maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determine the recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of somatic mutations in driver genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in alcohol-induced stimulation between medication periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective response to alcohol between medication periods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in risky decision-making after alcohol administration between medication periods
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: OCD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery 15 index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Combined major block-related adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Test-retest Reliability of the SECEL:HR Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Means, Standard Deviations of SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Means, Standard Deviation of VHI Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in proportion of scheduled appointments attended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Overall Response (Prior CAR T-Cell Therapy Cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients who decide to enroll in a glioma clinical research
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of glioma study participants who remain in clinical study until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall percent agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of BKV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change In LogMAR Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample Inadequacy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraceptive Efficacy as Assessed by the At-Risk Pearl Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleaning time of postoperative recurrent vitreous hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of varices requiring EVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IgG EBNA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients for Whom the Intervention Components Were Feasible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Patient Intervention Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Caregiver Intervention Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of SARS-CoV-2 nucleic acid particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mechanical power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability and ease-of-use perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of brain tissue volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes